ClinicalTrials.gg
Active, not recruitingNCT06537804PLUSUpdated Apr 15, 2025

Project Lung Cancer Screening in Southern Denmark

An interventional study of Screening by low-dose CT scan in Lung Cancer, sponsored by Odense University Hospital. Active, not recruiting at 2 sites in Denmark. Open to participants aged 60 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,332
Allocation
Randomized
Ages
60 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.

Enrollment
5th of 94
1,332 · median 158
Started
2024
with 10 others
No phase
46 of 124
14 open now
Primary completion
2026-12
later than 17 of 46 live
Registered
100th of 124
by date
Lead sponsor
7 of 124
Odense University Hospital

Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 5th largest by enrollment of the 94 interventional ones that give a count, is one of 11 that started in 2024, is one of 46 with no phase, reaches primary completion later than 17 of the 46 other live ones, and was the 100th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 60 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Lung Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

One thousand randomly selected voluntary citizens aged 60-74 years old, who are heavy current or former smokers with an increased risk of developing lung cancer may be included in the project. The participants will be identified through an initial questionnaire survey concerning smoking history and general health. Project participants are offered a low-dose CT (LDCT) scan annually for three consecutive years. In relation to the first scan, a lung function test will also be performed. The screening process will be evaluated for possible national implementation of a lung cancer screening program in Denmark.

Read the detailed description

This pilot study is a prospective interventional feasibility study. The primary goal is to evaluate the impact on healthcare organization, administration of resources and costs, and thereby assessing the feasibility of implementing systematic screening for lung cancer among people at high risk in Denmark (current or former heavy smokers). The pilot study will be performed on Funen in the Region of Southern Denmark and will run over three years (2024-2026). One thousand randomly selected participants aged 60-74 years old, who meet the screening criteria, will receive annual LDCT scans for three consecutive years.

Data will be collected continuously throughout the study period. The analysis method will focus on descriptive statistics to display questionnaire response and participation rates, and assess the impact of screening on healthcare organization and resources. Furthermore, the result including direct and indirect effects of the screening process (e.g. number of positive findings, false positive results, and follow-up rates). The analyses will also include healthcare economics including resource consumption as well as qualitative assessments to describe potential differences between the screening population versus a corresponding control group of heavy smokers. Finally, the radiologists' assessments of the project's LDCT scans are compared to the assessment of an artificially intelligent algorithm to explore the opportunities of supporting a future national screening program.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
60 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heavy smokers (≥ 30 pack years) or citizens with a PLCOm2012 calculated 6-year risk of lung cancer > 2%.
  • Age: 60-74 years old
  • Residence on Funen and surrounding islands

Exclusion criteria

Exclusion Criteria:

  • Cancer treatment or follow-up (except non melanoma skin cancer and similar low malignant cancers) within the past 12 months
  • CT scan performed within the past 12 months
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,332 participants (actual)

Study arms

  • Other
    Intervention

    Low-dose CT scans are performed once a year from 2024 to 2026 to screen for lung cancer including a lung function test the first year of attendance (2024).

    Radiation: Screening by low-dose CT scan

  • No intervention
    Control

    Citizens from the cohort who are randomized to no intervention.

Interventions

  • RadiationScreening by low-dose CT scan

    Screening for lung cancer by low-dose CT scan

06

What researchers measure

Primary outcomes

  1. Lung cancer screening cost-effectiveness analysis quantified in the form of incremental cost-effectiveness ratio threshold

    ratio

    Time frame: Up to 36 months

Secondary outcomes

  1. Characteristics of citizens from the cohort based on registry data

    Registry data

    Time frame: Up to 36 months

  2. Participation rate

    Number and percentage of citizens completing the screening trial

    Time frame: 36 months (complete study period)

  3. Dropouts

    Number and percentage of citizens included that dropout during the study period

    Time frame: 36 months (complete study period)

  4. Lung cancer found on low dose CT-scans

    Number and percentage

    Time frame: Baseline, after 1 year, after 2 years

  5. Inconclusive or non-malignant findings on low dose CT scans

    Number and percentage

    Time frame: Baseline, after 1 year, after 2 years

  6. FEV1

    Measured in liters by a lung function test

    Time frame: Baseline

  7. FVC

    Measured in liters by a lung function test

    Time frame: Baseline

  8. Treatment diagnose - cancer

    number and percentage of treatments by action diagnosis related to cancer

    Time frame: 36 months (complete study period)

  9. Hospitalization time

    Hospitalization time related to lung cancer diagnosis measures in days

    Time frame: 36 months (complete study period)

  10. Treatment diagnose - any other disease (found on low dose CT scans)

    number and percentage of treatment diagnosis related to findings of other diseases (by action diagnosis)

    Time frame: 36 months (complete study period)

  11. Referral to follow-up procedures

    Number of referrals

    Time frame: 36 months Entire study period

  12. Self reported health and quality of life assessed by the EQ-5D-5L questionnair

    level of percieved problems are coded from level 1 to 5 in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression"

    Time frame: Baseline and after 2 years

  13. Self-reported smoking status

    Yes/no/former smoker

    Time frame: Baseline, after 1 year, after 2 years

  14. All-cause-mortality

    Number of deaths in both groups (intervention/no intervention)

    Time frame: 36 months (the entire study period)

  15. Gender

    Male/female

    Time frame: Baseline

  16. Weight

    Kilogram

    Time frame: Baseline

  17. Height

    Centimeters

    Time frame: Baseline

  18. Smoking history

    according to the PLCOm2012 risk model

    Time frame: baseline

  19. Total time consumption of extra work at involved departments: department of lung diseases, department of radiology and department og pulmonary diseases

    hours

    Time frame: 36 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 28 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Aug 5, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06537804
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Aug 5, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 15, 2025

Study contacts

Michael Stenger, Consultant
study director · Odense University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion